The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation.
Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives.
Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.
“As an ambitious organization, we knew we needed a leader with a breadth of experience who can push us to the next level,” says Patti Pearce, The Max Foundation CFO and VP of Administration. “I have total confidence in Wilma’s leadership and experience to drive success.”
Wilma will join The Max Foundation’s Seattle headquarters office and oversee The Max Foundation’s development and communication departments.
“I am honored to have the opportunity to join The Max Foundation,” says Wilma. “I’ve been impressed with the organization from the start and feel connected to the mission of providing dignity and hope to cancer patients worldwide.”
Please join us in welcoming Wilma Comenat as The Max Foundation’s Vice President of Development.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
We are delighted to announce that John Menapace has joined the Max Foundation as CFO/VP of Administration. John brings demonstrated business leadership to his new role with a background comprising more than 20 years of experience in driving growth and profitability, across Fortune 50, Big 5, non-profit, and start-up companies. His prior roles include positions….
Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….
IPIG joins Max’s Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) and will provide medical education and training on PNH care and management Max will provide access to innovative treatment as part of the multi-stakeholder collaboration focused on eradicating survival disparities in 53 low-resource countries People living with this rare blood disease require frequent….
